OGEDA

Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com

#SimilarOrganizations #People #Financial #Website #More

OGEDA

Social Links:

Twitter

Industry:

Biotechnology Health Care Health Diagnostics Pharmaceutical

Founded:

1994-01-01

Address:

Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Country:

Belgium

Website Url:

http://www.ogeda.com

Total Employee:

11+

Status:

Active

Contact:

(327)134-8500

Email Addresses:

[email protected]

Total Funding:

26 M EUR

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Amazon

Similar Organizations

calimmune-logo

Calimmune

Calimmune is a clinical-stage gene therapy company.

Current Employees Featured

not_available_image

Graeme Fraser
Graeme Fraser Chief Scientific Officer and Director, Drug Discovery @ Ogeda
Chief Scientific Officer and Director, Drug Discovery

Founder

pierre-nokin_image

Pierre Nokin

Investors List

vesalius-biocapital-partners_image

Official Site Inspections

http://www.ogeda.com

Host Informations
Whois Informations

Loading ...